

# Anne Santerre Henriksen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5886485/publications.pdf>

Version: 2024-02-01

7  
papers

106  
citations

1683934

5  
h-index

1588896

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. <i>Clinical Microbiology and Infection</i> , 2021, 27, 671-686.	2.8	54
2	<i>Staphylococcus aureus</i> from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3453-3461.	1.3	15
3	Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013â€“2015. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1653-1659.	1.3	13
4	<i>In vitro</i> activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014â€“2018 studies in France. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab081.	0.9	10
5	Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014&ndash;2015. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1309-1320.	1.1	6
6	<i>In vitro</i> activity of cefiderocol against Gram-negative bacterial pathogens in Germany. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 12-17.	0.9	3
7	<i>In vitro</i> activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016â€“19). <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac030.	0.9	2